ReviewJournal of neurology2018
Myasthenia gravis and infectious disease.
Review in Journal of neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 6 syntheses or guidelines pooled it, 149 citations in OpenAlex.
- Myasthenia Gravis With Acetylcholine Receptor Antibodies in the Very Old: Treatment Challenges and Diagnostic Pitfalls.European journal of neurology · 2026Pooled it
- Association between vaccination and myasthenia gravis: a systematic review and meta-analysis.Frontiers in immunology · 2026Pooled it
- Characteristics, treatment, and outcomes of Myasthenia Gravis in COVID-19 patients: A systematic review.Clinical neurology and neurosurgery · 2022Pooled it
- The Association Between Asthma and Risk of Myasthenia Gravis: A Systematic Review and Meta-analysis.Lung · 2021Pooled it
- A Systematic Review of the Potential Implication of Infectious Agents in Myasthenia Gravis.Frontiers in neurology · 2021Pooled it
- Nocardiosis-an uncommon infection in patients with myasthenia gravis: report of three cases and review of literature.BMJ case reports · 2020Pooled it
- Changes in corticosteroid and non-steroidal immunosuppressive therapy with long-term zilucoplan treatment in generalized myasthenia gravis.Journal of neurology · 2025Trial
- Possible involvement of viral infection in the pathogenesis of myasthenia gravis.Journal of neurovirology · 2026Review
- Hsa_circ_0000313/miR-1224-3p/MKNK2 Axis Modulates CD4Mediators of inflammation · 2026Article
- Article
- Rehabilitation for functional enhancement of myasthenia gravis: A systematic review and meta-analysis.eNeurologicalSci · 2025Review
- The Etiology Analysis of Myasthenia Gravis with In-Hospital Mortality in the Neurocritical Care Unit.Neurocritical care · 2025Article
- Anxiety in Myasthenia Gravis Patients Throughout the COVID-19 Pandemic-Prevalence, Risk Factors, and Association With Vaccination Status.Brain and behavior · 2025Article
- Case Report: Eculizumab in highly active myasthenia gravis complicated by severe infections.Frontiers in immunology · 2025Article
- Myasthenia gravis and community-acquired pneumonia: therapeutic challenges.Frontiers in pharmacology · 2025Review
- Cryptococcosis in patients with myasthenia gravis: clinical characteristics and management strategy.Frontiers in cellular and infection microbiology · 2025Article
- Understanding autoimmune response after SARS-CoV-2 infection and the pathogenesis/mechanisms of long COVID.Medical review (2021) · 2024Review
- The Risk of Exacerbation of Myasthenia Gravis After COVID-19 Omicron Infection.Brain and behavior · 2024Article
- Article
- Clinical Characteristics and Outcomes of Generalized Myasthenia Gravis in Malaysia: A Single-Center Experience.Journal of clinical neurology (Seoul, Korea) · 2024Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeMyasthenia gravis (MG) is an autoimmune disease with muscular weakness as the only symptom, and often with immunosuppressive treatment. All these aspects could have relevance for the risk of infections as well as their prophylactic and curative treatment.
methodsThis is a review article, where Web of Science has been searched for relevant key words and key word combinations. Full papers were selected first by title and then by abstract. RESULTS AND
conclusionsMG can be triggered and worsened by infections. No virus or other pathogen has been proven to have a specific link to MG. Treatment with immunosuppressive drugs and thymectomy implies a slightly increased risk for infections. Infections should be actively treated, but a few antibiotics are avoided due to potential interference with neuromuscular transmission. Hospitalization and intensive care may be necessary during infections because of MG deterioration and risk of insufficient respiration. Vaccinations are generally recommended in MG, but live microorganisms should be avoided if possible in immunosuppressed patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.